



Statement

Start of a Japanese Clinical Study of TAK-919, Moderna's COVID-19 Vaccine Candidate

- Administration of Moderna's vaccine candidate to the first subject in a Japanese clinical study

Osaka, JAPAN, January 21, 2021 - Takeda Pharmaceutical Company Limited ([TSE:4502/NYSE:TAK](https://www.takeda.com/stock)) ("Takeda") has initiated a clinical phase 1/2 study in Japan of TAK-919, Moderna's COVID-19 vaccine candidate. TAK-919 is the Japanese development code for Moderna's mRNA-1273 vaccine candidate. This study is a placebo-controlled study to evaluate the safety and immunogenicity of the mRNA-1273 vaccine in 200 adult subjects. The first subject in the clinical study received the vaccine today.

More detailed information about this study is available at [ClinicalTrials.gov](https://clinicaltrials.gov) (only available in English) and the [Takeda website](#) (only available in Japanese).

As [announced on October 29, 2020](#), Takeda will import and distribute 50 million doses of Moderna's COVID-19 vaccine candidate, mRNA-1273 (TAK-919), starting in the first half of 2021, pending licensure in Japan.